Respiratory · Clinical trials
Alpha-1 Antitrypsin Deficiency Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About alpha-1 antitrypsin deficiency — and why its trials are hard
Alpha-1 antitrypsin deficiency (AATD) is an inherited disorder in which mutations (most commonly the Z allele) reduce circulating alpha-1 antitrypsin, a protease inhibitor that protects lung tissue from neutrophil elastase. Low levels lead to early-onset emphysema, particularly in smokers, while polymerised protein retained in hepatocytes can cause liver disease. Management centres on smoking cessation, standard COPD therapies, vaccination and, for liver disease, transplantation. The disease-specific therapy is intravenous augmentation therapy using pooled human plasma-derived alpha-1 proteinase inhibitor (A1-PI), which raises serum and lung antitrypsin levels above a protective threshold. Products include Prolastin, Zemaira, Aralast and Glassia. Regulatory approval was based on biochemical efficacy (achieving target serum levels) rather than hard clinical outcomes, and randomised evidence for slowing emphysema progression is limited: the RAPID trial demonstrated a significant reduction in the decline of CT-measured lung density, though effects on FEV1 and exacerbations were not clearly established. Augmentation does not treat the associated liver disease. Newer approaches, including RNA-targeted therapies for the liver phenotype, remain investigational.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Alpha-1 proteinase inhibitor (human), pooled A1-PI (Prolastin (also Zemaira, Aralast, Glassia)) | (unverified) Prolastin first approved 1987; RAPID trial published 2015 | Chronic augmentation/maintenance in adults with AATD and clinical emphysema | RAPID (phase 3/4, Lancet 2015) for A1-PI (Zemaira/Respreeza) | Rate of decline in lung density measured by CT densitometry | Significant slowing of annual lung-density decline versus placebo; note limited RCT evidence for FEV1 or exacerbation benefit |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in alpha-1 antitrypsin deficiency development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Inhaled alpha-1 antitrypsin (aerosolised AAT augmentation) — Randomised trials of inhaled AAT (e.g., Kamada inhaled AAT programme) | Did not meet primary clinical endpoints (e.g., time to exacerbation) sufficient for approval | Insufficient lung interstitial delivery to protective levels and endpoint/powering challenges; specific trial values (unverified) |
Choosing the right endpoint
Primary endpoints that matter in alpha-1 antitrypsin deficiency trials
- Serum alpha-1 antitrypsin level (trough) — Biochemical surrogate; augmentation aims to exceed the ~11 uM (~0.57 g/L) protective threshold
- CT lung densitometry — Sensitive measure of emphysema progression; primary endpoint in the RAPID trial
- FEV1 decline — Traditional COPD endpoint but relatively insensitive in AATD trials
- Exacerbation frequency — Clinically meaningful but not robustly improved in augmentation RCTs
- Mortality / lung transplant-free survival — Long-term outcomes rarely powered in AATD studies
How iNGENū runs alpha-1 antitrypsin deficiency trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Alpha-1 Antitrypsin Deficiency clinical trials — FAQs
What is the disease-specific treatment for AATD lung disease?
Does augmentation therapy have strong outcome evidence?
Does augmentation treat the liver disease?
Ready to discuss your alpha-1 antitrypsin deficiency trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal